| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Sec'y; Chief Compliance & G.c. | Sec'y; Chief Compliance & G.c.
1 company
Scott Terrillion last filed a Form 4 in February 2025, as Sec'y; Chief Compliance & G.c. at TVRD. Scott Terrillion's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Scott Terrillion a strong insider score of 90/100, based on 12 past trades. Over a 12-month horizon, all 12 of those trades were profitable, with an average 12-month return of +61.3%.
At the last filing, the largest reported position was 7,190 shares of TVRD. The TVRD filings lean toward selling, a net 56,064 shares.
Scott Terrillion has 29 Form 4 filings on record from March 2018 to February 2025, all as Sec'y; Chief Compliance & G.c. at Tvardi Therapeutics (TVRD), 2018–2025.
The 39 reported transactions were 19 open-market sales, 14 stock awards and 6 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 19 sales worth about $567K.
The largest open-market sale was 4,004 shares of TVRD at an average $19.33 on February 25, 2021, about $77K.
1 of the 5 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other 4 were not.
Shares as reported in the last Form 4 for each company; the most recent is from February 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | TVRD Tvardi Therapeutics, Inc. | Sec'y; Chief Compliance & G.c. | Sell | 163 | $4.76 | $775.88 | -2.2% | +108.2% | -72.2% | |
| Apr 5, 2024 | TVRD Tvardi Therapeutics, Inc. | Sec'y; Chief Compliance & G.c. | Sell | 2,753 | $0.83 | $2,284.99 | -3.0% | -67.4% | -54.3% | |
| Feb 29, 2024 | TVRD Tvardi Therapeutics, Inc. | Sec'y; Chief Compliance & G.c. | Sell | 3,293 | $0.89 | $2,930.77 | -3.5% | -27.4% | -53.1% | |
| Jun 23, 2023 | TVRD Tvardi Therapeutics, Inc. | Sec'y; Chief Compliance & G.c. | Sell10b5-1 | 2,483 | $3.51 | $8,715.33 | -2.7% | -50.6% | -92.0% | |
| Apr 4, 2023 | TVRD Tvardi Therapeutics, Inc. | Sec'y; Chief Compliance & G.c. | Sell | 2,481 | $4.91 | $12,181.71 | -2.7% | -38.8% | -80.9% | |
| Mar 3, 2023 | TVRD Tvardi Therapeutics, Inc. | Sec'y; Chief Compliance & G.c. | Sell | 6,256 | $9.71 | $60,745.76 | -6.3% | -69.9% | -90.8% | |
| Feb 8, 2023 | TVRD Tvardi Therapeutics, Inc. | Sec'y; Chief Compliance & G.c. | Sell | 7,770 | $0.53 | $4,118.10 | -7.6% | -64.2% | -95.5% | |
| Dec 21, 2022 | TVRD Tvardi Therapeutics, Inc. | Sec'y; Chief Compliance & G.c. | Sell | 2,561 | $11.27 | $28,862.47 | -2.5% | -51.4% | -94.7% | |
| Apr 1, 2022 | TVRD Tvardi Therapeutics, Inc. | Sec'y; Chief Compliance & G.c. | Sell | 1,642 | $11.91 | $19,556.22 | -1.6% | -27.9% | -61.2% | |
| Mar 3, 2022 | TVRD Tvardi Therapeutics, Inc. | Sec'y; Chief Compliance & G.c. | Sell | 1,787 | $11.38 | $20,336.06 | -1.7% | -24.7% | -7.2% |